Anbio Biotechnology (NNNN)
| Market Cap | 1.22B |
| Revenue (ttm) | 8.65M |
| Net Income (ttm) | 6.40M |
| Shares Out | 43.89M |
| EPS (ttm) | 0.15 |
| PE Ratio | 188.58 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 35,724 |
| Open | 25.82 |
| Previous Close | 27.65 |
| Day's Range | 25.82 - 28.49 |
| 52-Week Range | 6.05 - 55.65 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 7, 2026 |
About NNNN
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021... [Read more]
Financial Performance
In 2025, Anbio Biotechnology's revenue was $8.65 million, an increase of 5.64% compared to the previous year's $8.19 million. Earnings were $6.40 million, an increase of 169.86%.
Financial StatementsNews
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. Covering both mosquito-borne dis...
Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions
Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Coll...
Anbio Biotechnology Announces Closing of Initial Public Offering
Frankfurt am Main, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the pro...
Anbio Biotechnology Announces Pricing of Initial Public Offering
Frankfurt am Main, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (the “Company” or “Anbio”), a global diagnostic company dedicated to the advancement of medical technology and the pro...